ACP
VNDA icon

Acuta Capital Partners’s Vanda Pharmaceuticals VNDA Stock Holding History

Acuta Capital Partners’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-162,600
Closed -$2.59M – 75
2016
Q4 		$2.59M Sell
162,600
-83,395
-34% -$1.34M 0.96% 25
2016
Q3 		$4.09M Buy
+245,995
New +$3.31M 1.54% 24
2016
Q1 		– Sell
-27,952
Closed -$260K – 53
2015
Q4 		$260K Buy
+27,952
New +$279K 0.12% 49

Other funds holding VNDA

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Acuta Capital Partners's VNDA Position: Q1 2017 in Review

Acuta Capital Partners sold out of Vanda Pharmaceuticals (VNDA) in Q1 2017, closing a stake of 162,600 shares — an estimated $2.59M sold.

Acuta Capital Partners first reported a position in VNDA in Q4 2015 and held it in 3 quarters. The position peaked at $4.09M in Q3 2016. 136 funds tracked by Wall St. Rank hold VNDA as of Q1 2017.

  • Acuta Capital Partners reported no remaining Vanda Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Acuta Capital Partners sold 162,600 Vanda Pharmaceuticals shares in Q1 2017, an estimated $2.59M.
  • Acuta Capital Partners first reported a position in Vanda Pharmaceuticals in Q4 2015 and held it in 3 quarters.
  • Acuta Capital Partners's Vanda Pharmaceuticals position peaked at $4.09M in Q3 2016.
  • 136 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2017.

Based on Acuta Capital Partners's 13F filing for Q1 2017, filed 15 May 2017.